The research compound in Mysimba^®

Mysimba^® is a weight management medicine from Currax Pharmaceuticals. Its active compound is Naltrexone/Bupropion — which is what this catalogue supplies, as a research material.

This is not Mysimba^®, and NOVALYTE LABS has no affiliation with Currax Pharmaceuticals. We supply the compound Naltrexone/Bupropion for laboratory research only — not for human consumption, diagnostic, therapeutic or veterinary use. Mysimba^® is a trademark of Currax Pharmaceuticals, referenced here only to identify the compound.

Mysimba is the European brand for the naltrexone and bupropion combination; the same combination is marketed as Contrave in the United States.

It is unusual in this category for acting on neither the incretin nor the amylin system: bupropion is a dopamine and noradrenaline reuptake inhibitor, naltrexone an opioid antagonist, and the combination is studied for its effect on hypothalamic appetite signalling.

The combination is supplied here as a research material, not as the branded medicine.

Naltrexone/Bupropion in this catalogue

Other brands using Naltrexone/Bupropion

The same compound is marketed under more than one brand, usually because each brand carries a different approved indication.